Eli Lilly
NICE Still Not Recommending Leqembi, Kisunla for Alzheimer's in Updated Draft Guidance
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
Premium
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such programs are necessary.
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
Lilly recently terminated its own mutant PI3Kα inhibitor program following disappointing Phase I results.
Ovation.io Collecting WGS, Clinical Data From 8,500 Patients on GLP-1 Meds
The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.
Nov 20, 2024
Jul 31, 2024
May 29, 2024
FDA Lowers Pediatric Age for Eli Lilly's Retevmo
Apr 8, 2024
Apr 4, 2024